Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etoposide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.94 |
| ▸ | TOP2B known ✓ | Q02880 | 4/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.94 |
| ▸ | GAA | P10253 | 5/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | MEN1 | O00255 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.94 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.94 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.94 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.94 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etoposide SCHEMBL14484918 | 1.00 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL16246162 | 1.00 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL3622 | 1.00 | CYP3A4 (0.94) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL14401267 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL22594950 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL24482748 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL13114424 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL20598257 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL23064754 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL6361654 | 0.97 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| CN-115531535-A | Compositions and methods for photochemical control of mTOR signaling and mTOR-dependent autophagy | 香港大学 | 2022-12-30 | — | — | CN | disclosed |
| WO-2020243359-A1 | COMPOUNDS FOR USE IN ANTI-CANCER IMMUNOTHERAPY | SIRENAS LLC (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-3630083-A1 | DIMETHYL-NONATETRAENYL-TRIMETHYL-CYCLOHEXYL COMPOUNDS AND USES THEREOF | The Regents of The University of Michigan (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3534905-A1 | SMALL MOLECULE DUAL INHIBITORS OF EGFR/PI3K AND USES THEREOF | The Regents of The University of Michigan (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3471712-A1 | SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2019005754-A1 | CANCER TREATMENT | THE CLEVELAND CLINIC FOUNDATION (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2018217873-A1 | DIMETHYL-NONATETRAENYL-TRIMETHYL-CYCLOHEXYL COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2018081719-A1 | SMALL MOLECULE INHIBITORS OF NEK2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2017223086-A1 | SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2014066615-A1 | CANCER STEM CELL VACCINATION AND TREATMENT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2013119923-A1 | DIFFERENT STATES OF CANCER STEM CELLS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-08-15 | — | — | WO | disclosed |
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2013078392-A1 | METHODS AND COMPOSITIONS INVOLVING INDUCED SENESCENT CELLS FOR CANCER TREATMENT | THE UNIVERSITY OF CHICAGO (US) | 2013-05-30 | — | — | WO | disclosed |
| EP-2536431-A2 | COMPOSITIONS AND METHODS FOR INHIBITING MMSET | The Regents of The University of Michigan (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2536741-A2 | GENE FUSION TARGETED THERAPY | The Regents of The University of Michigan (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103028-A2 | COMPOSITIONS AND METHODS FOR INHIBITING MMSET | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103011-A2 | GENE FUSION TARGETED THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103016-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010068720-A2 | PODOPHYLLOTOXIN INHIBITORS OF TOPOISOMERASE II | AUSPEX PHARMACEUTICAL, INC (US) | 2010-06-17 | — | — | WO | disclosed |